Print EmailText:SmallMediumLarge

Donald E. Segal

Partner


Donald Segal practices primarily in food, drug and medical device regulation. Mr. Segal provides counsel to pharmaceutical, medical device, biologic, food and cosmetic companies regulated by the FDA. He has practiced food and drug law, health care law and administrative law for over 25 years in national law firms and at the FDA, where he served as Associate Chief Counsel.

Mr. Segal focuses on providing strategic advice, and legal and regulatory counsel to a variety of product manufacturers, distributors, hospitals and service providers regarding market entry issues and compliance matters involving marketed products. For example, he assists clients in responding to preparing pre-market submissions and the review of labeling and advertising. He advises clients on recalls, adverse events reporting and current good manufacturing practices (GMPs). Mr. Segal has assisted clients with responding to inspectional findings and warning letters, preparing regulatory sections of securities filings, and preparing and negotiating licensing and contractual agreements. He has also represented companies in litigation regarding injunctions, seizures and intellectual property issues.

Representative Experience

  • Represented financial institutions in their due diligence and regulatory analysis of potential acquisitions of medical device, drug and food companies.
  • Represented a medical device company regarding a denial of a 510(k) submission, and, after meeting with FDA and revising the submission, securing FDA clearance.
  • Represented a major food manufacturer in the conduct of a recall and resolution of subsequent insurance and product liability claims.
  • Represented a drug company in petitioning FDA to expand the scope of an OTC drug monograph.
  • Represented a biomedical company in resolving 510(k) and inspectional deficiencies.
  • Represented a manufacturer of medical and laboratory instruments in developing a strategy to seek new indications.
  • Submitted complaints to FDA regarding misleading competitor advertising and promotion.
  • Evaluated the regulatory implications of health care-related software and software-related service offerings.
  • Provided advice regarding corporate integrity agreements.
  • Provided advice regarding food additive petitions and food standards of identity.


Related Events
September 18, 2009
June 17-20, 2008
October 26, 2006
Publications
February 23, 2007
"Regulatory Pathway for 'Biosimilar' Products Debated," Legal Backgrounder, February 23, 2007.

Donald E. Segal

The Atlantic Building
950 F Street, NW
Washington, D.C. 20004-1404
Phone: 202-239-3449
Fax: 202-654-4939

Education

  • Boston College
    (J.D., 1972)
  • Brandeis University
    (B.A., 1969)

Admitted to Practice

  • District of Columbia
  • Massachusetts